As part of our ongoing series focussing on new registrations in Australia, we have added a product review of the use of Selexipag in the treatment of patients with pulmonary arterial hypertension.
This review discusses its pharmacological properties, dosage and administration, efficacy and tolerability, and evidence in support of the use of Selexipag as demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Dr John Feenstra, the lead physician for pulmonary hypertension in the Queensland Lung Transplant Service at the Prince Charles Hospital, and the Director of the Wesley Pulmonary Hypertension Unit.
Please login below to download this issue (PDF)